Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from SII

Sprott Unearths A Metals ETF That Targets Hidden Gems

Sprott Inc. (NYSE:SII) introduced a new actively managed ETF that invests through the entire metals and mining lifecycle.

Benzinga

Sprott Stock Glitters Like Gold

Sprott (SII) shows strong technical momentum and just hit a new 52-week high. SII has a 100% technical “Buy” signal via Barchart. The alternative asset manager also pays a dividend, which could make its shares more attractive. Despite bullish technicals and analyst ratings, SII is volatile and speculative. Today’s Featured...

Barchart

Parents claim death due to Covishield, to file lawsuit against Serum Institute of India

Parents nationwide intend to sue Pune's Serum Institute of India (SII) and government officials responsible for the Covid vaccine rollout. They allege their children's deaths resulted from vaccine side effects. Parents of 8 victims from Kerala, Mumbai, Coimbatore, Hyderabad, Bengaluru, and Kapurthala. This action follows AstraZeneca's acknowledgment in a UK…

The Times of India

From analysis to the latest developments in health,
read the most diverse news in one place.

TOI Health News Morning Briefing | SII says vaccine side effects were disclosed in packaging, air inside car can be carcinogenic, common mistakes that affect Vitamin D absorption, how magnesium deficiency affects the body and more

Covishield side effects in packaging: Serum Institute of India

The Times of India

Covishield manufacture stopped since December 2021; have disclosed all side effects in packaging: Serum Institute of India

Amidst huge uproar regarding the side effect of Covishield, the Serum Institute of India has said that it has stopped the manufacture and supply of additional doses of Covishield from December 2021 and this was done in view of the significantly decreasing demand for previous vaccines.

The Times of India

India gets its own HPV vaccine to stop 70,000 women dying of cervical cancer a year

It has taken 18 years for India to produce its own affordable version to tackle the country’s second-biggest cause of cancer deaths among women

The Guardian - UK

New COVID variant JN.1: Health Ministry says no need for booster dose

Following the Union Health Ministry direction that States be alert and prepared for any possible surge in COVID-19 cases following the emergence of the new variant JN.1, senior health officials said that there is no move to recommend administration of vaccine booster dose for India.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Responsible ESG investing in the Global South requires overcoming the Global North's saviour complex

ESG standards (Environment, Social and Governance) are metrics designed to guide responsible investing. The “S” in ESG has evolved into the financial innovation of social impact investing (SII), which promotes social benefits such as environmental protection, gender equality and human development, and also generates profits for beneficiaries and investors.

The Conversation

Top 3 Asset Management Stocks to Buy in the Industry

The asset management industry is well-positioned for robust growth and expansion, driven by high demand for efficient asset utilization and management, the growing popularity of ESG and alternative investments, and rapid digitalization. Hence, top asset management stocks Sprott (SII), Diamond Hill Investment (DHIL), and Silvercrest (SAMG) could be solid buys…

StockNews.com

Fingers ‘turned to powder’: the maimed workers of India’s auto hub

Poor training, shoddy equipment leave thousands of workers injured in India’s auto hub.

Al Jazeera

MoU signed for infectious diseases, pandemic preparedness centre

The Hindu

Rising COVID Cases News From China Is Concerning: SII CEO Adar Poonawala, Urges People Not To Panic

Raising concern on the rising COVID-19 cases in neighbouring China, Serum Institute of India (SII) CEO Adar Poonawala on Wednesday asked the people not to panic because of India's "excellent vaccination coverage and track record". Read on for details:

Dynamite News

DGCI allows Serum Institute to export malaria vaccine to U.K.

The Drugs Controller General of India (DCGI) has granted permission to send two lakh doses of the vaccine

The Hindu

Bombay HC issues notice to Central govt, Bill Gates, Serum Institute over plea on alleged Covid vaccine death

Dilip Lunawat in his petition, "blamed the Government and others for misrepresenting the facts about the COVID-19 vaccine by making false claims about its safety and 'forcing' medical practitioners to take the vaccine. Read more on Dynamite News:

Dynamite News

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

India-made HPV vaccine to cost ₹200

CERVAVAC, India’s first indigenously developed vaccine to prevent cervical cancer, has been developed by SII

Reuters

Indian vaccine giant Serum plans African plant in global expansion

The Serum Institute of India (SII), the world's biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling COVID-19 shots, its CEO told Reuters on Monday.

The Hindu

SII lowers each dose of Covovax jab from ₹900 to ₹225 excluding taxes

The price of the vaccine, Covovax, is learnt to have been revised on the CoWIN portal.

The Times of India

Bombay HC: Does SII have policy to buy back surplus vaccine vials?

MUMBAI: Bombay high court on Thursday directed Serum Institute of India (SII) to inform if it has a policy to buy back surplus Covishield vaccine vials.

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

SII urges Centre to use 10 crore Covishield doses offered by GAVI

Amid surge in cases, manufacturer warns of wastage

The Hindu

Coronavirus updates | February 8, 2022

India records 65,000 new cases, 1,169 deaths

The Hindu

DGCI gives nod to SII’s proposal to manufacture vaccine against omicron for test, analysis

SII has obtained permission and licence to manufacture SARS-CoV-2rS drug substance for examination, test and analysis.

The Times of India

Will work for equitable health, says Dr Poonawalla

PUNE: Covishield maker Serum Institute of India (SII)'s founder-owner Dr Cyrus Poonawalla has been named among this year's awardees for Padma Bhushan.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Union Health Ministry

the Union Health Ministry

Serum Institute of India

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.